VistaGen Therapeutics

VistaGen Therapeutics

A company developing medicines for depression and other central nervous system disorders

VistaGen Therapeutics is a publicly owned, clinical-stage biopharmaceutical company based in San Francisco, California that was founded in 1998 by Ralph Snodgrass. The company is focused on developing treatments for depression and other central nervous system (CNS) disorders including, major depressive disorder, neuropathic pain, social anxiety disorder, and suicidal ideation.

Products

VistaGen's product pipeline consists of three items, AV-101, PH10, and PH94B. AV-101 is an oral NMDAR GlyB (N-methyl-D-aspartate receptor glycine B) antagonist, which is a type of glutamate receptor modulators having the potential to treat MDD. Phase 2 clinical trials designed to evaluate the efficacy and safety of it's adjunctive use is ongoing. The US FDA has granted Fast Track designation for AV-101 as both a potential adjunctive treatment of MDD and as a non-opiod treatment for neuropathic pain. The company has also received Notices of Allowances from IP Australia and the Japan Patent Office (JPO) .

PH94B is an intranasal treatment for the rapid onset, on demand treatment of social anxiety disorder (SAD) symptoms. The treatment is developed from VistaGen's proprietary compounds called pherines. Another treatment being developed from pherines, is PH10, which activates nasal chemosensory receptors that in turn engage GABA (gamm-aminubutyic acid) and CRH (corticotropin-releasing hormones) neurons in the hypothalamus, amygdala, prefrontal cortex, and hippocampus. As another potential treatment for MDD, VistaGen is preparing to advance PG10's development in Phase 2b clinical trials.

Timeline

1998

VistaGen Therapeutics was founded by H. Ralph Snodgrass.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

H. Ralph Snodgrass

Founder, President, Director & Chief Scientific Officer

Jerrold D. Dotson

VP & CFO and Secretary

Mark A. McPartland

VP of Corporate Development

Mark A. Smith

Chief Medical Officer

Oscar Baranchuk

Investor

Rajiv Gujral

Investor

Shawn K. Singh

Director & CEO

Susan E Caldwell, PhD

Employee

Further reading

Title
Author
Link
Type
Date

This Analyst Sees More Upside for VistaGen Therapeutics (VTGN) Stock; Here's Why

Jason Cohen

Web

VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10

VistaGen Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 27, 2020
BioSpace
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 18, 2020
BioSpace
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.